JSPR vs. RGNX, TRML, MBX, ACB, TERN, FHTX, TSHA, CYRX, ANNX, and CRVS
Should you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include REGENXBIO (RGNX), Tourmaline Bio (TRML), MBX Biosciences (MBX), Aurora Cannabis (ACB), Terns Pharmaceuticals (TERN), Foghorn Therapeutics (FHTX), Taysha Gene Therapies (TSHA), Cryoport (CYRX), Annexon (ANNX), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry.
Jasper Therapeutics vs.
REGENXBIO (NASDAQ:RGNX) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking and earnings.
In the previous week, Jasper Therapeutics had 2 more articles in the media than REGENXBIO. MarketBeat recorded 3 mentions for Jasper Therapeutics and 1 mentions for REGENXBIO. Jasper Therapeutics' average media sentiment score of 0.64 beat REGENXBIO's score of -0.28 indicating that Jasper Therapeutics is being referred to more favorably in the news media.
Jasper Therapeutics has a net margin of 0.00% compared to REGENXBIO's net margin of -283.19%. Jasper Therapeutics' return on equity of -67.64% beat REGENXBIO's return on equity.
REGENXBIO has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500.
REGENXBIO presently has a consensus target price of $33.45, indicating a potential upside of 360.17%. Jasper Therapeutics has a consensus target price of $64.44, indicating a potential upside of 979.83%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than REGENXBIO.
REGENXBIO received 394 more outperform votes than Jasper Therapeutics when rated by MarketBeat users. However, 90.00% of users gave Jasper Therapeutics an outperform vote while only 65.62% of users gave REGENXBIO an outperform vote.
88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 13.1% of REGENXBIO shares are owned by insiders. Comparatively, 2.7% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Jasper Therapeutics has lower revenue, but higher earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Jasper Therapeutics beats REGENXBIO on 12 of the 17 factors compared between the two stocks.
Get Jasper Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jasper Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:JSPR) was last updated on 2/22/2025 by MarketBeat.com Staff
Free JSPR Stock Alerts